Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, UPA at doses of 15 mg and 30 mg showed higher efficacy than placebo for treating severe alopecia areata in adults and adolescents over 24 weeks, with a safety profile similar to approved uses.

This study found that baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata, with similar improvements observed in both clinician-reported and patient-reported measures.

This paper discusses two preclinical models for studying alopecia areata and finds that testing new therapeutic agents should involve both the C3H/HeJ mouse model and the humanized mouse model for comprehensive insights.

Both atopy and eosinophilia are linked to more severe hair loss in people with alopecia areata.

Severe alopecia areata in children greatly affects their mental and social well-being, and addressing these challenges is crucial.

This study found that combining PRP with topical minoxidil or finasteride significantly improved hair density and thickness, with patient satisfaction highest for multiple treatment combinations and longer durations.

Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.

In this study, researchers identified subgroups of patients with severe alopecia areata treated with baricitinib who experienced early, gradual, or late hair regrowth, finding that response was influenced by baseline disease severity and duration of hair loss.

In this study, patients with severe alopecia areata treated with baricitinib over 152 weeks experienced sustained patient-reported improvements in scalp, eyebrow, and eyelash hair regrowth, with higher responders observed in the 4mg dose group compared to the 2mg group.

This study found that alefacept showed no significant improvement in treating severe alopecia areata compared to placebo over a 24-week period.

This article discusses the role of interleukin-15 and Janus kinase inhibitors in alopecia areata based on a murine model and reports no new experimental results.

In this case report, a 9-year-old horse was diagnosed with alopecia areata contributing to Malassezia dermatitis, involving lymphocyte infiltration and symptoms consistent with yeast presence.

This study suggests that allogenic human mesenchymal stem cell treatments have potential therapeutic effects by inducing immune tolerance and anti-inflammatory effects in severe alopecia areata patients.

This study found that upadacitinib significantly improved hair regrowth compared to placebo in adults and adolescents with severe alopecia areata, and demonstrated a positive benefit-risk profile.

In this update, researchers incorporated TGA-approved Janus Kinase inhibitors into the Australian treatment guidelines for chronic, moderate to severe Alopecia areata, aiming to enhance recommended therapies by providing guidance on the use and management of these systemic medications.

In this study, withdrawal of baricitinib therapy in patients with severe alopecia areata who had achieved hair regrowth led to a loss of benefit in almost all patients, suggesting that continued treatment is necessary to maintain hair regrowth.

This study suggests that DPCP treatment can be effective and safe for severe alopecia areata in children, with maintenance therapy potentially reducing relapse rates.

This study found that severe alopecia areata significantly impacts quality of life, mental health, and daily activities, particularly among women and those with a longer disease duration.

This case report found that oral tofacitinib treatment resulted in more than 90% hair regrowth in a 6-year-old with severe alopecia areata, with no relapse after dose reduction.

This study reported that therapeutic make-up significantly improves the long-term quality of life for patients with facial dermatoses, showing a sustained benefit one year after application, particularly in younger patients.

This study found that 79% of adolescents with moderate-to-severe alopecia areata treated with baricitinib experienced significant scalp hair regrowth, although further research is needed to confirm these results.

This study found that cyclosporine A may lead to partial hair regrowth in 50% of patients with severe alopecia areata who do not respond to standard treatments.

In this study, tofacitinib was reported to improve scalp hair regrowth in patients with severe alopecia areata, alopecia totalis, and alopecia universalis, showing a higher response in alopecia areata.

This study found that oral JAK inhibitors, ruxolitinib and tofacitinib, are effective and well-tolerated for treating severe alopecia areata, with a similar degree of hair regrowth and relapse rates, but ruxolitinib induced faster initial hair regrowth.

This review summarizes findings on the long-term use of tofacitinib for severe alopecia areata, reporting its potential as a promising treatment option.

In this analysis, safety data from two clinical trials showed that baricitinib for severe alopecia areata had predictable side effects like infections and elevated CPK, with some serious adverse events noted at low incidence rates; no deaths were reported.

This article hypothesizes that apremilast, a phosphodiesterase 4 inhibitor, could be a targeted treatment for alopecia areata due to its ability to suppress interferon-gamma production, but reports no new clinical results.

This review highlights the possible role of T regulatory cells in the immune-related mechanisms of alopecia areata but reports no new clinical findings.

In this study, oral steroid pulse therapy was found to be as effective and well-tolerated as intravenous pulse therapy in treating severe alopecia areata, especially when started within one year of disease onset.